Why Wegovy Did Not Work for You: the Most Likely Reasons

You may not have reached the dose that actually works

The starting dose of Wegovy is 0.25 mg, a tolerance dose whose job is to let your body adjust, not to produce weight loss. The licensed maintenance dose is 2.4 mg, reached through a slow titration of roughly one step every four weeks. A lot of people who feel Wegovy did not work for them stopped, switched, or ran into supply problems before they finished that climb.

This matters because the evidence base (including the STEP 1 trial published in the New England Journal of Medicine) is built on participants reaching and sustaining 2.4 mg. Results at lower doses are meaningfully smaller. If you spent several months at 0.5 mg or 1.0 mg because titration was paused, or because supply of the higher pens was interrupted, the medicine was not failing you so much as it was not yet doing its job.

Worth checking: did you complete the full titration? And how long did you spend at 2.4 mg before concluding it was not working? Prescribers generally expect to see meaningful progress after around 16 weeks at the maintenance dose, less than that is too early to judge. Our semaglutide overview covers the full dose schedule if you want to map where you got to.

Biology, adherence and timing all affect whether semaglutide works

Even at the correct dose, Wegovy does not work identically for everyone. That is not a failure of willpower, it reflects genuine biological variation in how people respond to GLP-1 receptor agonism. Factors that research consistently links to reduced response include: not adjusting diet alongside treatment (the licence specifies a reduced-calorie diet and increased activity as part of the package), significant psychological stress, disrupted sleep, and some medicines that counteract appetite regulation.

Timing of injections can also quietly undermine results. Wegovy is a once-weekly injection; taking it at irregular intervals, or skipping doses during periods when side effects felt difficult, effectively keeps you at sub-therapeutic levels for stretches of time. The NHS medicines page for semaglutide sets out clearly that consistent weekly dosing is the basis for the treatment working as intended.

Gastrointestinal side effects (nausea, loose stools, indigestion) lead some people to stop earlier than planned. That is understandable. But those effects are usually most pronounced in the first few weeks after a dose increase and tend to settle. If they were the reason you stopped, it is worth telling a prescriber: there are practical strategies to manage them, including slowing the titration pace.

When semaglutide genuinely is not the right match

Sometimes Wegovy has not worked because semaglutide itself is simply not the most effective option for a given person's biology. This is a real phenomenon, not a polite way of saying you did not try hard enough. The evidence on non-response to semaglutide shows that a meaningful minority of people lose less than 5% of their body weight at maintenance dose, and NICE's guidance for both semaglutide and tirzepatide notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing should be reviewed.

In that situation, switching to tirzepatide (Mounjaro) is clinically reasonable and increasingly common. Tirzepatide activates both the GLP-1 and GIP receptors, a dual mechanism that the SURMOUNT-5 head-to-head trial found produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. The weight-loss treatment overview explains both options side by side if you are weighing up a change.

A prescriber at a GPhC-registered pharmacy reviews your history before recommending anything, your previous dose, how long you were on it, what you experienced, and whether tirzepatide is clinically suitable. That review is the right place to make this decision; it is not something to navigate alone based on what you read online.

How to move forward if you are in this position

The honest answer is that the next step depends on which of the reasons above applies to you. If you are asking why Wegovy has not worked for you specifically, the answer usually sits in one of three areas: dose, duration, or biology. If you completed a full course at 2.4 mg and saw minimal results, a switch to a dual-receptor agonist deserves serious consideration. If side effects were the barrier, a slower titration managed with prescriber support often makes the difference.

What none of these paths requires is a referral or a waiting list. A private consultation through a GPhC-registered online pharmacy means your situation is reviewed by a named prescriber (not an automated triage tool) the same day you submit your consultation. If treatment is appropriate, it is dispatched the same day for next-working-day DPD delivery. The medication arrives in plain, unbranded packaging; you can track it on your phone. That part is straightforward. The harder part, and the more important one, is working out whether Wegovy can simply not work for certain people, or whether the right dose and support would change the outcome. Hearing from others who have been through the same process can also help, and reading about whether Wegovy worked for people in similar situations gives useful real-world context before you decide. That is exactly the conversation our prescribers are set up to have, check your eligibility here if you want to start it.